PE Tech Report


Like this article?

Sign up to our free newsletter

KKR to invest in Arbor Pharmaceuticals

KKR is to acquire a significant minority stake Arbor Pharmaceuticals. Financial terms of the transaction have not been disclosed.

Acquired by its current investor group in 2010, Arbor markets branded prescription products for the cardiovascular, hospital, and paediatric markets as well as generic products through its Wilshire division. The company has completed over twenty acquisition, licensing, or product development transactions over the past four years and has multiple products filed with the FDA as well as several branded and generic products in late-stage development.

“Arbor is led by an accomplished management team with a track record of building and scaling specialty pharmaceutical platforms. We believe that Arbor, with its diversified product portfolio, late-stage development pipeline, and proven business development acumen, is well positioned for continued growth,” says Ali Satvat, Director on KKR’s Health Care investing team.

“Arbor remains committed to creating value for patients by identifying, developing, and bringing to market improved medicines with a focus on quality. Arbor and our new investment partner KKR maintain a shared vision for continuing to provide quality products that offer significant clinical benefits to patients,” says Ed Schutter, President and CEO of Arbor.

“We are pleased to be adding KKR, with its extensive industry experience, to our shareholder base. We selected KKR based on a number of factors, including compatibility with Arbor and a shared vision for achieving future growth. This is an important next step as we continue building a fully integrated pharmaceutical company focused on products that improve patients’ lives,” says Jason Wild, Chairman of the Board of Arbor and President of JW Asset Management LLC.

Like this article? Sign up to our free newsletter